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Abstract
Background: Aurora kinases play an essential role in orchestrating chromosome alignment, segregation and
cytokinesis during mitotic progression, with both aurora-A and B frequently over-expressed in a variety of human
malignancies. Over-expression of the ABC drug transporter proteins P-glycoprotein (Pgp) and Breast cancer
resistance protein (BCRP) is a major obstacle for chemotherapy in many tumour types with Pgp conferring
particularly poor prognosis in acute myeloid leukaemia (AML). Barasertib-hQPA is a highly selective inhibitor of
aurora-B kinase that has shown tumouricidal activity against a range tumour cell lines including those of leukaemic
AML origin.
Methods: Effect of barasertib-hQPA on the pHH3 biomarker and cell viability was measured in a panel of
leukaemic cell lines and 37 primary AML samples by flow cytometry. Pgp status was determined by flow cytometry
and BCRP status by flow cytometry and real-time PCR.
Results: In this study we report the creation of the cell line OCI-AML3DNR, which over-expresses Pgp but not
BCRP or multidrug resistance-associated protein (MRP), through prolonged treatment of OCI-AML3 cells with
daunorubicin. We demonstrate that Pgp (OCI-AML3DNR and KG-1a) and BCRP (OCI-AML6.2) expressing AML
cell lines are less sensitive to barasertib-hQPA induced pHH3 inhibition and subsequent loss of viability
compared to transporter negative cell lines. We also show that barasertib-hQPA resistance in these cell lines
can be reversed using known Pgp and BCRP inhibitors. We report that barasertib-hQPA is not an inhibitor of
Pgp or BCRP, but by using
14[C]-barasertib-hQPA that it is effluxed by these transporters. Using
phosphoHistone H3 (pHH3) as a biomarker of barasertib-hQPA responsiveness in primary AML blasts we
determined that Pgp and BCRP positive primary samples were less sensitive to barasertib-hQPA induced pHH3
inhibition (p = <0.001) than samples without these transporters. However, we demonstrate that IC50 inhibition
of pHH3 by barasertib-hQPA was achieved in 94.6% of these samples after 1 hour drug treatment, in contrast
to the resistance of the cell lines.
Conclusion: We conclude that Pgp and BCRP status and pHH3 down-regulation in patients treated with barasertib
should be monitored in order to establish whether transporter-mediated efflux is sufficient to adversely impact on
the efficacy of the agent.
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The mammalian aurora kinases aurora-A, aurora-B and
aurora-C comprise a family of serine/threonine kinases
that are essential for cell cycle control and mitotic pro-
gression [1]. Interest in the auroras has intensified since
the observation that both aurora-A and B are over-
expressed in a wide variety of tumour types [2-5]
including those of leukaemic origin [6,7]. The implica-
tion of the auroras in tumourigenesis and the fact that
that they are kinases, amenable to small molecule inhi-
bition, makes them attractive targets for anticancer drug
development. Success of agen t ss u c ha si m a t i n i bi nt h e
treatment of chronic myelogenous leukaemia has
increased confidence that small-molecule inhibitors of
specific kinases may prove to be highly effective antican-
cer agents [8]. Despite having high sequence homologies
in their kinase domains the three aurora members have
very distinct subcellular localizations and functions dur-
ing mitosis [9]. Aurora-B is a chromosomal passenger
protein which undergoes dynamic localization during
mitosis, associating first to the inner centromeric region
during prometaphase, and then to the spindle midzone
and midbody during late anaphase and telophase sug-
gesting a role in cytokinesis [1,10]. Aurora-B is the cata-
lytic component of the chromosomal passenger complex
(CPC), which is composed of three additional non-cata-
lytic subunits that direct its activity: survivin, inner cen-
tromere protein (INCENP) and borealin. The CPC
orchestrates the spindle checkpoint and ensures the
accurate segregation of chromatids and correct microtu-
bule/kinetochore attachment during mitosis and cyto-
kinesis [11]. Aurora-B is also known to phosphorylate
Histone H3 (pHH3) at the serine 10 position during
mitosis [12,13]. Inhibition of Histone H3 phosphoryla-
tion has been reported to prevent initiation of chromo-
some condensation and entry into mitosis [14]. Aurora-
A is known to phosphorylate numerous centrosomal
proteins and primarily functions in centrosomal regula-
tion and mitotic spindle formation with loss of Aurora-
A function leading to cell cycle arrest and monopolar
mitotic spindles [9]. Aurora-C is the least studied of the
aurora family and is highly expressed in the testis where
it is thought to have a specific role in the regulation of
chromosome segregation during male meiosis [15].
More recently aurora-c has been identified at low levels
in sixteen other tissues including bone marrow with stu-
dies suggesting that it has a complementary role to aur-
ora B and Survivin as a chromosomal passenger protein
[16,17].
A growing number of aurora kinase inhibitors have
been described that show anti-tumour activity in vivo.
Three non-selective aurora kinase inhibitors ZM447439,
Hesperadin and VX-680 all induce similar phenotypes
when tested in cell based assays [18-20]. Specifically, all
three inhibit phosphorylation of Histone H3 on serine
10 and induce DNA endoreduplication in the absence of
cytokinesis, results that suggest that their cellular effects
are largely due to the inhibition of aurora-B [21]. We
have previously reported the same cellular phenotype in
AML cell lines treated with barasertib-hQPA [22].
Barasertib (formerly AZD1152) is a quinazoline pro-
drug which is converted in plasma to the more active
moiety barasertib-hQPA (AZD1152-hQPA) and it is the
more active barasertib-hQPA that has been supplied by
AstraZeneca for the purpose of this study. Barasertib-
hQPA is an aurora kinase inhibitor that has potent
selectivity for inhibition of aurora-B (Ki: aurora-B = 0.36
nM) compared to aurora-A and C (Ki:a u r o r a - A=1 3 6 9
nM and aurora-C = 17.0 nM) and a panel of 50 other
kinases [23]. We have however recently reported that
the FMS-like tyrosine kinase 3 internal tandem duplica-
tion (FLT3-ITD) mutation is a secondary target for bar-
asertib-hQPA in AML cells [22]. Barasertib has been
shown to significantly inhibit the growth of human
colon, lung and haematological tumour xenografts in
immunodeficient mice and as such has been selected for
clinical evaluation [23,24]. It has also shown tumourici-
dal activity against a panel of tumour cell lines including
those of acute myeloid leukaemia (AML) origin
[22,25-27]. Results of a Phase 1 study in AML were
reported at ASH 2010 (Abstract 656) and a Phase II
study is ongoing.
A M Li sah e t e r o g e n e o u sc l o n a ld i s o r d e ro fh a e m o -
poietic progenitor cells where both failure to differenti-
ate and over proliferation results in accumulation of
non-functional cells termed myeloblasts [28]. Intrinsic
resistance or treatment-induced acquired resistance is
one of the major obstacles to the effective treatment of
patients with AML. While nearly 80% of younger AML
patients may initially achieve complete remission with
current therapy most will relapse with resistant disease
[29]. Clinical outcomes in the elderly have been even
more modest as these patients do not tend to tolerate
intensive chemotherapy regimens and frequently have
poor cytogenetics [30]. Less than 10% of older patients
with AML will achieve long-term disease free survival
with conventional chemotherapy [31]. This inability to
successfully treat AML patients, particularly the elderly,
underlies the continuing need to develop new treat-
ments for AML.
The development of multidrug resistance (MDR) is
frequently observed in the treatment of cancer, and is a
phenomenon that allows tumour cells that have been
exposed to one cytotoxic agent to develop cross resis-
tance to a range of structurally and functionally unre-
lated compounds. In patients with AML, MDR can be
present intrinsically at diagnosis or can arise during che-
motherapy as well as at relapse. ATP binding cassette
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Page 2 of 13(ABC) transporter-mediated active efflux of cytotoxic
agents is the most well characterized mechanism by
which cancer cells develop MDR, particularly after
repeated cycles of chemotherapy [32]. The ABC trans-
porters are an evolutionary extremely well conserved
family of transmembrane proteins expressed in most
cells and involved in the ATP driven transport of a huge
variety of substrates including sugars, peptides, inorganic
ions, amino acids, proteins, vitamins and metallic ions
[33]. The family currently consists of 49 members, 13 of
which are associated with chemotherapeutical drug
transport and drug resistance [34]. The genes can be
divided into subfamilies based on similarity in gene
structure resulting in seven mammalian ABC gene sub-
families (ABCA, B C, D, E F and G family). The most
widely studied members ABCB1 (MDR1/P-glycopro-
tein), ABCC1 (multidrug resistance protein, MRP1) and
ABCG2 (breast cancer resistance protein, BCRP) have
the ability to export a wide variety of structurally unre-
lated chemotherapeutic compounds from cancer cells,
thereby conferring MDR to these cell [33].
Despite improvements accomplished in the last thirty
years with the use of combination of cytarabine and inter-
calating agents, the overall prognosis of adult AML
remains poor. One of the best characterized resistance
mechanisms in AML is drug extrusion mediated by P-gly-
coprotein (Pgp). Expression of the MDR1 gene coding for
Pgp is high in elderly patients with AML and is associated
with worse complete remission rates [30]. Multidrug resis-
tance-associated protein 1 (MRP1) has also been shown to
contribute to MDR in AML [30], whereas other studies
have been unable to detect any correlation between MRP1
protein expression and clinical response in AML patients
[35]. Breast cancer resistance protein (BCRP) has been
shown to be overexpressed in 33% of AML patients with
normal karyotype and to significantly affect the duration
of complete remissions [36]. Another study showed BCRP
expression to be a prognostic factor in AML patients trea-
ted with daunorubicin and mitoxantrone but not with
idarubicin [37]. Conversely, another group found a prog-
nostic value for Pgp and MRP1 but suggested BCRP has a
limited function in the drug efflux related resistance in
AML [38]. It has recently been reported that the amplifica-
tion of genes that encode for Pgp and BCRP can confer
resistance to barasertib-hQPA in colon and pancreatic car-
cinoma cell lines [39].
In this study we will investigate the specificity of bara-
sertib-hQPA in AML cell lines and primary samples in
relation to their ABC transporter status.
Results
Cell line validation
The OCI-AML3DNR cell line was created as described
in the Methods section. The short tandem repeats
(STR) analysis of the OCI-AML3DNR and OCI-AML6.2
cell lines was shown to be identical to the parent OCI-
AML3 cell line indicating that there were no significant
genetic changes.
Pgp and BCRP expressing cell lines are less sensitive to
barasertib-hQPA induced pHH3 inhibition and
subsequent loss of viability
The effects of barasertib-hQPA were examined in loga-
rithmically growing OCI-AML3, OCI-AML3DNR, OCI-
AML6.2, KG-1a and U937 leukaemic cell lines. Func-
tional Pgp was determined using rhodamine 123 (R123)
retention and the known Pgp modulator cyclosporine A
(CSA) as a positive control modulator [40], with the KG-
1a (p = 0.002) and daunorubicin selected OCI-
AML3DNR (p = 0.039) cell lines showing high Pgp func-
tional expression (Figure 1A). Functional BCRP was mea-
sured using BODIPY-prazosin (BODIPY) retention and
Fumitremorgin C (FTC) [41] as a modulator with only
the stably transfected BCRP OCI-AML6.2 (p = 0.015) cell
line showing any functional BCRP activity. High OCI-
AML3DNR (p = 0.003) and KG-1a (p = 0.006) Pgp levels
were also observed when we measured Pgp protein using
the MRK-16 monoclonal antibody (Figure 1B). To verify
that MRP expression had not also been elevated in our
daunorubicin selected cell line we used a Calcein-AM
retention assay with the MRP modulator MK-571 [42]
and compared MRP function to the adriamycin selected,
MRP positive, HL-60ADR cell line [43] (Figure 1C). No
significant increase in MRP function was detected in the
OCI-AML3DNR cells (p = 0.358) in contrast to that seen
in the HL-60ADR cells (p = 0.004) when compared to
the parent cell lines. An in house flow cytometry protocol
for measuring pHH3 expression was used and has been
described in detail previous l y[ 2 2 ] .T h eb a s a lr a n g eo f
pHH3 expression in the cell lines was 1.8-4.8% of total
cells. After 24 hours, at concentrations of 0-1000 nM
barasertib-hQPA, inhibition of pHH3 was achieved in
both ABC transporter negative cell lines (Figure 2A(i)
and 2B(i)). There was significant inhibition of pHH3 in
the U937 (p = 0.001) and OCI-AML3 (p = 0.003) cells at
30 nM barasertib-hQPA before complete inhibition at
100 nM. The ABC transporter positive cell lines were all
much more resistant to pHH3 inhibition at barasertib-
hQPA concentrations up to 1000 nM. The decrease in
pHH3 seen at 300 nM and 1000 nM barasertib-hQPA in
the OCI-AML6.2 cells was not statistically significant (p
= 0.408/0.207). Seventy-two hours incubation with bara-
sertib-hQPA caused loss of viability in both transporter
negative cell lines with an almost complete loss of viabi-
lity achieved at 30 nM (Figure 2A(ii) and 2B(ii)). Again,
the transporter positive cells were much more resistant,
with loss of viability seen only at high dose barasertib-
hQPA.
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is effluxed by these transporters
To determine whether barasertib-hQPA is able to mod-
ulate Pgp or BCRP function we compared it to known
modulators using fluorescent dye retention assays. Bara-
sertib-hQPA had no effect on R123 retention in the Pgp
positive OCI-AML3DNR cell line (Figure 3A(i)) in con-
trast to the marked increase in retention seen with CSA
(Figure 3A(ii)). Likewise barasertib-hQPA had no effect
on BODIPY retention in the BCRP positive OCI-
AML6.2 cell line (Figure 3B(i)) in contrast to the
increase in retention seen with FTC (Figure 3B(ii)). In
these assays barasertib-hQPA did not appear to be a
modulator of Pgp or BCRP. We therefore decided to
employ the UIC2 shift assay; which is an indirect way of
measuring unlabelled Pgp substrates [44]. The reactivity
of the UIC2 antibody with Pgp is increased by the addi-
tion of Pgp transported compounds. We tested baraser-
tib-hQPA in the UIC2 shift assay using the Pgp positive
KG-1a cell line and the known Pgp substrate vinblastine
[44] as a positive control (Figure 3C). No shift in UIC2
binding was seen with barasertib-hQPA treatment. Also,
co-incubation of barasertib-hQPA and vinblastine, failed
to affect any shift seen with vinblastine alone. This assay
failed to show that barasertib-hQPA is a Pgp substrate.
However it did not prove the converse as a few Pgp
substrates such as etoposide fail to alter UIC2 binding
depending on their stoichiometry and Pgp ATPase activ-
ity [45]. To categorically determine if barasertib-hQPA
was being effluxed by Pgp and BCRP we used radio-
labelled barasertib-hQPA to measure its cellular reten-
tion (Figure 3D). In this assay CSA and FTC increased
retention of [
14C]-barasertib-hQPA in both OCI-
A M L D N R( p=0 . 0 0 4 )a n dO C I - A M L 6 . 2( p=0 . 0 0 5 )
cells respectively. The modulators increased retention of
[
14C]-barasertib-hQPA to at least the concentration seen
in the ABC transporter negative/barasertib-hQPA sensi-
tive OCI-AML3 cell line.
Culture with known inhibitors sensitize Pgp and BCRP
positive AML cells to barasertib-hQPA
Sub-toxic doses of the Pgp inhibitor CSA and also of the
BCRP inhibitor FTC were added to cell culture with 10-
1000 nM barasertib-hQPA (Figure 4). Addition of CSA
sensitizes the Pgp positive cell lines OCI-AML3DNR and
KG-1a to pHH3 down-regulation with complete loss of
pHH3 seen at 24 hours with 100 nM barasertib-hQPA
(Figure 4A(i)). There is no statistical significance in the
decrease in pHH3 at 10 nM barasertib-hQPA plus CSA
in the OCI-AML3 cells, or in the increase in pHH3 in
KG-1a cells with the same treatment, both p = 0.145.
The same effect is seen in 72 hour cell viability with a
marked decrease in viability at 10 nM and complete loss
of cell viability at 100 nM barasertib-hQPA with the
addition of CSA (Figure 4A(ii)). The MRP inhibitor MK-
571 did not sensitize OCI-AML3DNR cells to barasertib-
hQPA induced pHH3 inhibition, or loss of viability,
confirming that resistance is not due to any elevated
MRP expression in these cells (Data not shown). Addi-
tion of FTC also clearly sensitizes the BCRP positive cell
line OCI-AML6.2 to pHH3 down-regulation at baraser-
tib-hQPA concentrations as low as 10 nM (p = 0.021)
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Figure 1 Expression of ABC transporters in AML cell lines.A ,
Pgp function was measured using R123 accumulation and
Cyclosporine A as a positive control modulator. BCRP was measured
similarly with BODIPY-prazosin accumulation and Fumitremorgin C
as the modulator. (*p = 0.039/**p = 0.015/***p = 0.002) (analysed
using paired samples t-test), +95% confidence interval). B, Pgp
protein expression was determined using the MRK-16 monoclonal
antibody (*p = 0.003/**p = 0.006). C, MRP function was measured
using Calcein-AM accumulation and MK-571 as a modulator (*p =
0.358/**p = 0.004). Columns, mean of three experiments; bars, SD.
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Page 4 of 13with complete down-regulation of pHH3 seen at 100 nM
barasertib-hQPA with the addition of FTC (Figure 4B(i)).
Complete loss of cell viability at 72 hours was achieved
at 100 nM barasertib-hQPA with the addition of FTC
(Figure 4B(ii)).
Pgp and BCRP positive primary AML samples are less
sensitive to barasertib-hQPA induced pHH3 inhibition
The level of pHH3 detectable in untreated cell lines was
low (1.8-4.8% of total cells) and expression in primary
cells was expected to be even lower, as a very small
population of cells are actively dividing at the time of
sampling. Because of this we pre-incubated primary
samples with a cytokine cocktail to drive the cells into
cycle before treatment with barasertib-hQPA. Cellular
proliferation in primary samples has been confirmed
previously using [
3H]-Tdr uptake with pHH3 expression
correlating extremely well with the amount of prolifera-
tion [22]. Mean basal pHH3 expression in the primary
samples was 3.01% (range, 0.04-13.14%) of total cells.
We have previously reported that basal pHH3 expres-
sion in our primary samples shows significant correla-
tion with aurora-B mRNA levels (p = 0.015) [22]. pHH3
expression was measured in 37 primary samples after 1
hr’s treatment with 300 nM barasertib-hQPA (Figure
5A). IC50 was achieved in all but 2 samples (94.6%) with
a mean down-regulation of 78% (Range, 32.7-100%). Of
the primary samples tested 9/37 (24.3%) were positive
for Pgp and 9/35 (25.7%) positive for BCRP. Mean
MRK-16 test/control mean fluorescence intensity (MFI)
in the primary samples was 1.13 (range, 0.72-2.92).
Mean CSA modulation ratio in the primary samples was
1.74 (range, 0.91-9.16). Five samples co-expressed Pgp
and BCRP such that we found a significant correlation
(p = 0.008, r2 = 0.238) between Pgp and BCRP expres-
sion in our primary samples. The percentage of Pgp and
BCRP positive samples and the co-expression correla-
tion agrees with previously published data [36]. Pgp
positive samples were significantly (p = <0.001) less sen-
sitive to barasertib-hQPA induced pHH3 inhibition than
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Figure 2 Specificity of barasertib-hQPA in AML cell lines. A(i), B(i) Effect of 24 hours barasertib-hQPA exposure on pHH3 expression in
leukaemic cell lines (*p = 0.001/**p = 0.003/***p = 0.207) (analysed using paired samples t-test), +95% confidence interval). A(ii), B(ii) Effect of 72
hours barasertib-hQPA exposure on viable cell count in leukaemic cell lines measured using 7AAD and fixed stained cells. Columns/lines, mean
of three experiments; bars, SD.
Grundy et al. BMC Cancer 2011, 11:254
http://www.biomedcentral.com/1471-2407/11/254
Page 5 of 13Pgp negative samples (Figure 5B). BCRP positive pri-
mary samples were also significantly (p = <0.001) less
sensitive to barasertib-hQPA induced pHH3 inhibition
compared to BCRP negative samples (Figure 5C). How-
ever, a sharp distinction between cell lines and primary
samples was noted. Whereas the transporter-expressing
cell lines were insensitive to down-regulation of pHH3
at concentrations of up to 1000 nM barasertib-hQPA
even after 24 hours, IC50 pHH3 inhibition was achieved
in 94.6% of primary samples at 300 nM barasertib-
hQPA for one hour.
Discussion
The success of agents such as imatinib in the treatment of
chronic myelogenous leukaemia has lead to an increase in
confidence that small-molecule inhibitors of specific
kinases may prove to be highly effective anticancer agents
[8]. The aurora kinase family are essential for normal
mitotic progression and have attracted great interest as
potential new therapeutic targets. Overexpression of aur-
ora kinases have been reported in many tumour types and
linked to a poor prognosis. The aurora-B kinase specific
inhibitor barasertib-hQPA has shown tumouricidal activity
against a panel of tumour cell lines and xenograft models
including those of AML origin [22-24,27]. Our group have
recently reported that the FLT3-ITD mutation is a sec-
ondary target for barasertib-hQPA and that primary AML
samples with an ITD mutation in the FLT3 gene are parti-
cularly sensitive to the drug [22]. The FLT3 gene is one of
t h em o s tc o m m o n l ym u t a t e dg e n e si nA M Lw i t ht h e
FLT3-ITD mutation appearing in roughly 24% of cases
and being associated with a poor prognosis [46,47]. Bara-
sertib-hQPA is therefore of potential use as a future treat-
ment in AML.
Intrinsic MDR or treatment-induced MDR has histori-
cally been one of the major obstacles to the effective
treatment of patients with AML. Elevated expression of
the MDR1 gene coding for the drug efflux pump Pgp is
one of the best characterized resistance mechanisms in
AML with high expression in elderly patients particu-
l a r l ya s s o c i a t e dw i t hw o r s ec o m p l e t er e m i s s i o nr a t e s
[30]. The ABCG2 gene encoding BCRP has also been
shown to be overexpressed in AML patients and to sig-
nificantly affect the duration of complete remission [36].
Any potential new drug for the treatment of AML
should therefore be screened for its efficacy in patients
expressing high levels of these drug transporters.
Aurora-B is known to phosphorylate Histone H3
(pHH3) at the serine 10 position during mitosis [12,13].
We have previously demonstrated a method for measur-
ing pHH3 expression in our cell lines and more impor-
tantly in our primary samples and its subsequent down-
regulation after barasertib-hQPA treatment [22]. We
can therefore use pHH3 expression as a biomarker for
barasertib-hQPA activity. Initial experiments showed
that our Pgp positive (KG-1a) and BCRP positive (OCI-
AML6.2) cell lines were much less sensitive to baraser-
tib-hQPA in comparison to transporter negative cell
lines. This was seen at both the biomarker and
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Figure 3 There is no modulation of Pgp or BCRP function by
barasertib-hQPA. A, R123 accumulation in OCI-AML3DNR cells +/-
300 nM barasertib-hQPA (i) or 2.5 μg/ml CSA (ii). The dotted lines
are the 4°C R123 control. The solid black line is R123 + diluent
control and the solid grey line R123 + barasertib-hQPA (i) and R123
+ CSA (ii). B, BODIPY-prazosin accumulation in OCI AML6.2 cells +/-
300 nM barasertib-hQPA (i) or 10 μM FTC (ii). The dotted lines are
the 4°C BODIPY control. The solid black line is BODIPY + diluent
control and the solid grey line BODIPY + barasertib-hQPA (i) and
BODIPY + FTC (ii). Plots are representative of a single experiment
which was done in triplicate. C, UIC2 binding in KG-1a cells in the
presence of 5 μM vinblastine (i), 1 μM barasertib-hQPA (ii) or a
combination of both (iii). The dark filled line is the diluent control
and the light line indicates any shift. D, 300nM [
14C]-barasertib-
hQPA uptake in Pgp expressing OCI-AML3DNR cells +/- the Pgp
modulator CSA and in OCI-AML6.2 cells +/- the BCRP modulator
FTC. Pgp/BCRP negative OCI-AML3 cells have been used as a
positive control (*p = 0.004/**p = 0.005) (analysed using paired
samples t-test), +95% confidence interval). Diluent controls were
included for each modulator. Columns, mean of three experiments;
bars, SD.
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Page 6 of 13subsequent viability level. Because we had no parental
Pgp negative comparison for the KG-1a cell line we
wanted to create a Pgp expressing cell line from the
OCI-AML3 cells. The subsequently developed Pgp
expressing OCI-AML3DNR cell line was more resistant
to barasertib-hQPA compared to the sensitive OCI-
AML3 parent cells (Figure 2B). This resistance to bara-
sertib-hQPA in the transporter positive cell lines was
reversed when known inhibitors of Pgp and BCRP were
co-cultured with barasertib-hQPA (Figure 4). There was
an initial spike in KG-1a pHH3 levels at 10 nM baraser-
tib-hQPA with the addition of CSA (Figure 4A(i)). This
spike was also seen in the sensitive U937 cells also at 10
nM barasertib-hQPA (Figure 2A(i)) and to a lesser
extent in the OCI-AML3 cells (Figure 2B(i)) indicating
that CSA is sensitizing the Pgp expressing KG-1a cells
to barasertib-hQPA. By using
14[C]-barasertib-hQPA in
combination with known Pgp and BCRP inhibitors we
show definitively that the drug is being effluxed by these
transporters in the OCI-AML3DNR and OCI-AML6.2
cell lines.
Inhibiting Pgp as a way of reversing MDR has been
intensively studied for many years. Pharmacological
inhibition of Pgp by small-molecule antagonists has
been studied in several AML trials with various agents
but only yielding little clinical success [48-51]. Many of
these agents are substrates for other transporters and
enzyme systems resulting in unpredictable pharmacoki-
netic interactions in the presence of chemotherapy
agents. Recently more specific so called third generation
inhibitors of MDR have been developed that have the
potential to minimize any drug-drug interactions [52]. A
combination of these inhibitors with barasertib-hQPA
could circumvent any problem of drug efflux by ABC
transporters seen with this drug.
We measured pHH3 expression in 37 primary AML
samples cultured for one hour with or without baraser-
tib-hQPA. 9/37 (24.3%) were positive for Pgp and 9/35
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Figure 4 Specificity of barasertib-hQPA in AML cell lines in combination with ABC transporter modulators.A ,E f f e c to f2 4h o u r s
barasertib-hQPA exposure +/- 2.5 μg/ml CSA on pHH3 expression in OCI-AML3, OCI-AML3DNR and KG-1a cells (*p = 0.145/**p = 0.145)
(analysed using paired samples t-test), +95% confidence interval) (i). Effect of 72 hours barasertib-hQPA exposure +/-2.5 μg/ml CSA on viable cell
count (ii). B, Effect of 24 hours barasertib-hQPA exposure +/- 5 μM FTC on pHH3 expression in OCI-AML3 and OCI-AML6.2 cells (***p = 0.021) (i).
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Figure 5 Pgp and BCRP positive primary AML samples are less sensitive to barasertib-hQPA induced pHH3 inhibition.A ,F l o w
cytometric pHH3 expression in 37 primary AML samples pre-incubated with cytokine cocktail for 48 hours and then treated with 300 nM
barasertib-hQPA for 60 minutes. Pgp expression was determined by modulation of R123 efflux and MRK-16 expression. ABCG2 message levels
were measured using real-time PCR. B, Scatter plot demonstrating that Pgp positive primary samples are less sensitive to barasertib-hQPA
induced pHH3 inhibition than Pgp negative samples (p = <0.001), Mann-Whitney. C, Scatter plot demonstrating that BCRP positive primary
samples are less sensitive to barasertib-hQPA induced pHH3 inhibition than BCRP negative samples (p = <0.001), Mann-Whitney.
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Page 8 of 13(25.7%) were positive for BCRP with a significant cor-
relation (p = 0.008, r2 = 0.238) seen for co-expression.
This data agrees with results seen previously [36]. Pgp
positive samples were significantly less sensitive to bar-
asertib-hQPA induced pHH3 inhibition compared to
Pgp negative samples (p = 0.001) as were BCRP posi-
tive samples compared to BCRP negative samples (p =
0.001). Importantly though, >50% inhibition of pHH3
was still seen in all but 2 primary samples (94.6%). So
c e r t a i n l ya tt h el e v e lo ft h eb i o m a r k e rw es e eam u c h
better response in ABC transporter positive primary
samples than in transporter positive cell lines at the
corresponding dose of barasertib-hQPA. Whereas in
the transporter positive cell lines we demonstrated
efflux of barasertib-hQPA using radio-labelled drug it
is clear that all of our primary samples retained
enough drug to target the pHH3 biomarker. This dif-
ference in response may be explained by the ‘artifi-
cially’ high transporter expression seen in the cell
lines. For example, if we look at our measure of Pgp
function, the mean CSA modulation ratio in our pri-
mary samples was 1.74. Four times this was seen in
the Pgp expressing OCI-AML3DNR cell line and
greater than seven times seen in the Pgp expressing
KG-1a cell line. Likewise the amount of Pgp protein
measured using the MRK-16 antibody was two-folds
higher in the OCI-AML3DNR cells and seven-folds
higher in the KG-1a cells compared to the mean value
of 1.13 seen in primary samples.
Conclusions
MDR AML cell lines are a useful tool to model trans-
porter mediated drug resistance but their efflux activity
is extreme compared to that found in primary AML
samples. Most clinical trials with Pgp modulators have
been unsuccessful and thus the importance of efflux
pumps in AML chemoresistance is unclear. Clinical
trials with barasertib may help to resolve this issue,
since pHH3 is such a clear-cut marker of efficacy at the
cellular level. We conclude that Pgp and BCRP expres-
sion levels and pHH3 down-regulation in patients trea-
ted with barasertib should be monitored in order to
establish whether transporter-mediated efflux is suffi-
cient to adversely impact on the efficacy of the agent.
Methods
Materials
Materials were from Sigma (Poole, Dorset UK) unless
otherwise stated. Barasertib-hQPA was provided by
AstraZeneca (Cheshire, UK).
Cell lines
The OCI-AML3 myeloid leukaemia cell line was
obtained from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunschweig, Germany).
U937, HL-60 and KG-1a cell lines were from the
European Collection of Animal Cell Cultures (Salisbury,
UK). The ABCG2 stably transfected OCI-AML6.2 cells
were a gift from Dr. Jo Mountford (University of Glas-
gow, UK). The HL-60ADR [43] cell line was a gift from
Mark Center (Kansas State University, USA). U937, OCI-
AML3 and OCI-AML6.2 cell lines were maintained in
RPMI 1640 medium with 10% foetal calf serum (FCS;
First Link, Birmingham, UK), 2 mM L-glutamine, 100 U/
ml penicillin and 10 μg/ml streptomycin. The KG-1a cell
line was maintained as above with 20% FCS. All cultures
were kept at 37°C in 5% CO2 and all experiments were
performed with cell lines in log phase. Continued testing
to authenticate these cell lines was initially performed
using a panel of monoclonal antibodies and later by STR
fingerprinting. Mycoplasma testing was carried out routi-
nely using a Mycoalert mycoplasma detection kit (Lonza,
Rockland, USA) and following the manufacturer’s
instructions.
Selection of Daunorubicin resistant OCI-AML3 cells
OCI-AML3 cells were initially exposed to daunorubicin
(DNR) at a concentration of 10 nM, which represented
the IC50 concentration. Cells were seeded at 5 × 10
5/ml
in 50 ml of complete medium containing 10 nM DNR.
At days 3, 10 and 14, 50 ml of fresh culture medium
without DNR was added. At day 18 cells were pelleted
and re-suspended in 160 ml medium containing 10 nM
DNR. From day 26 to day 35 the DNR containing med-
ium was changed once per week. At day 35 there were
very few remaining viable cells, so cells were separated
over Histopaque to exclude dead cells and cell debris.
The remaining cells were re-suspended in 10 ml of
medium containing 10 nM DNR up until day 45 when
cell growth was seen. Cells were maintained at this drug
concentration until their growth rate approached that of
untreated OCI-AML3 cells. Over the next 10 weeks
cells were exposed to gradually increasing concentra-
tions of DNR up to a final concentration of 15 nM. By
using the R123 accumulation assay these cells were con-
firmed to have increased levels of Pgp function and
were subsequently cloned by limiting dilution. Cells
were serially diluted in 96 well plates down to a concen-
tration of 1 cell/well in medium containing 15 nM
DNR. Any cells showing outgrowth were then gradually
cultured in medium containing 15 nM DNR up to suffi-
cient numbers to be able to assay for Pgp protein and
function. One clone showed an increase in both Pgp
protein expression and function. This clone was named
OCI-AML3DNR and was then cultured under standard
conditions with 15 nM DNR and also cryo-preserved for
future use. DNR was removed from culture medium 7
days prior to any experimental procedure.
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Page 9 of 13OCI-AML3/OCI-AML3DNR/OCI-AML6.2 genetic analysis
DNA was prepared using a QIAamp DNA blood mini
kit (Qiagen, Crawley, UK) and 5 ng DNA was amplified
using the Powerplex 16 System (Promega, Southampton,
UK) to assess STR. The products were run on a 3130
Genetic Analyser and the data analysed using GeneMap-
per ID v3.2 software.
Patient samples
Presentation blood or bone marrow samples from multi-
ple centres were obtained at diagnosis from patients
with AML (excluding M3 subtype) and taken into pre-
servative-free heparin or into EDTA tubes. All samples
were pre-treatment and only samples received within 48
hours of being removed from the patient were analyzed.
Use of these samples was approved by the Nottingham
1 Research Ethics Committee (reference number 06/
Q2403/16). Mononuclear cells were isolated using a
standard density gradient/centrifugation method with
Histopaque and cryopreserved in liquid nitrogen. For
analysis, cryopreserved samples were thawed and rested
in culture medium enriched to 20% FCS for 90 minutes
before experimental procedures. Thawed and rested
samples were then subjected to viability analysis using
trypan blue exclusion and only samples with > 85%
post-rest viability were used.
Pgp protein expression - MRK-16 mAb
For Pgp protein expression cells were harvested, washed in
PBSAA, and 2 × 10
5 cells incubated with 1 μg MRK-16
anti-Pgp monoclonal antibody (Kamiya Biomedical) or
IgG2a isotype control (Dako) for 30 min at RT. Cells were
washed x3 in PBSAA and blocked in 80 μl2 0 %n o r m a l
rabbit serum for 30 min on ice. 5 μl FITC-conjugated goat
anti-mouse secondary antibody (Dako) was added and
cells incubated for 30 min on ice. Cells were washed twice
in PBSAA and cell line data collected using a FACS cali-
bur. Patient samples had the added step of the addition of
5 μl CD45PerCP (Becton Dickinson, UK) and 5 μlN o r m a l
Mouse serum before being washed twice in PBSAA and
collected using a FACS calibur. Labelling the patient sam-
ples with CD45PerCP allowed the leukemic (CD45 low/
side scatter low) cells to be gated [53].
Determination of Pgp, BCRP and MRP function
Functional Pgp expression was determined by modula-
tion of R123 efflux. Cells were resuspended at 1 × 10
6/
ml in culture medium and incubated (75 minutes, 37°c)
with R123 (200 ng/ml) with or without 2.5 μg/ml CSA
(supplied by the pharmacy of Nottingham City Hospital)
or diluent control. Control tubes containing R123 were
placed on ice to halt the reaction [53,54]. Functional
BCRP expression was measured similarly and was deter-
mined by modulation of BODIPY (Invitrogen) efflux.
Cells were resuspended at 1 × 10
6/ml in culture med-
ium and incubated (75 minutes, 37°c) with BODIPY (25
nM) with or without 10 μM FTC (Calbiochem) or dilu-
ent control. Control tubes containing BODIPY were
placed on ice. MRP function was determined by modu-
lation of Calcein-AM (Invitrogen) efflux [55]. Cells were
resuspended at 1 × 10
6/ml in culture medium and incu-
bated (75 minutes, 37°c) with Calcein-AM (0.1 μM) with
or without 40 μM MK-571 (Enzo life sciences, UK) or
diluent control. Control tubes containing Calcein-AM
were placed on ice. All tests were carried out in dupli-
cate. Cells were washed twice in PBSAA at 4°c, collected
using a FACS calibur (Becton Dickinson) and analysed
using Cellquest software. Mean fluorescence intensity
(MFI) of each sample in the FL1 channel was measured,
since this corresponds to R123/BODIPY retention. The
geometric mean fluorescence modulation ratio is calcu-
lated as: (MFI with modulator - cold control MFI)/(MFI
with diluent control - cold control MFI) [53,54].
Real-time PCR for ABCG2 message levels
Thawed and rested AML blasts were depleted of CD2
+
cells using Dynabeads (to deplete NK and T cells some of
which express ABCG2 mRNA [56]. RNA from CD2
depleted AML blasts and the ABCG2 positive OCI-
AML6.2 cell line was prepared using QIAamp RNA kits
with DNase treatment according to the manufacturer’s
instructions (Qiagen). Quantitative PCR was carried out as
previously reported [22]. The relative expression levels of
ABCG2 transcripts were calculated as the ratio between
the level of ABCG2 and the level of b2M. Both sets of real
time primers used have previously been published [57,58].
Determination of cell viability
This was done by a previously published in-house
method which makes use of an internal standard and
allows rapid enumeration of viable cells by flow cyto-
metric counting of cells labelled with 7-amino Actino-
mycin D (7-AAD) [59].
Histone H3 phosphorylation status
This was done by flow cytometry using anti-phospho-
histone H3 (Ser 10) mouse monoclonal antibody
(Upstate; now part of Millipore, Livingstone, UK) as pre-
viously described [22]. 37 primary AML samples were
cultured at 10
6/ml in RPMI 1640 with 10% FCS, 2 mM
L-glutamine, supplemented with 20 ng/ml interleukin
(IL)-3, 20 ng/ml stem cell factor, 20 ng/ml IL-6 +
25 ng/ml granulocyte colony-stimulating factor (R+D
Systems) + 0.07 μl/ml beta-mercaptoethanol for
48 hours. Samples were then treated with 300 nM bara-
sertib-hQPA for 60 minutes followed by pHH3 mea-
surement by flow cytometry. pHH3 expression was
calculated as a percentage of untreated controls.
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The reactivity of the UIC2 antibody with Pgp is
increased by the addition of Pgp transported compounds
and has been described by Park [44]. Briefly, cells were
resuspended at 5 × 10
5/ml in culture medium and incu-
bated for 10 minutes at 37°C, 5% C02.1μM barasertib-
hQPA or 5 μM of the known Pgp substrate vinblastine,
or both was added to cells in duplicate and incubated at
37°C, 5% C02 for 4 hours. Either 0.1 μg/ml UIC2 mono-
clonal antibody (Immunotech) or IgG2a isotype control
(Dako) was added to paired samples and incubated for a
further 15 minutes. Cells were washed twice in PBSAA,
resuspended in 20% Rabbit serum, and placed on ice for
30 minutes. 5 μl FITC-conjugated rabbit anti-mouse
secondary antibody (Dako) was then added to cells, and
following 30 minutes incubation on ice, cells were
washed twice and analysed by flow cytometry. An
increase in FL1 fluorescence compared to a paired con-
trol is taken to indicate the presence of a Pgp substrate.
Radio-labelled drug accumulation assay
Pgp expressing OCI-AML3DNR cells and the Pgp null
OCI-AML3 parent cell line were plated in duplicate
onto 12 well plates and pre-incubated for 30 mins with
or without the Pgp modulator CSA at 2.5 μg/ml. The
BRCP expressing OCI-AML6.2 cells were treated simi-
larly using BCRP null OCI-AML3 cells as a control and
10 μM FTC as the BCRP modulator. Medium contain-
ing 0.017 μCi radio-labelled [
14C]-barasertib-hQPA
(AstraZeneca, Cheshire, UK) was then added to give a
final drug concentration of 300 nM. The cultures were
incubated for 1 Hr at 37°c with agitation after 30 mins.
The radioactive medium was then aspirated and cells
washed twice with ice cold PBS before permeabilisation
with 1% sodium dodecylsulphate (Sigma). Cell extracts
were then added to scintillation fluid (Perkin Elmer) and
radioactive drug retention measured using a TRI-CARB
2100TR liquid scintillation analyser (Packard).
Statistical Analysis
Statistical analysis was carried out using the Statistical
Package for Social Sciences, version 16 (SPSS, Chicago,
IL, USA). P values of less than or equal to 0.05 were
considered to represent significance.
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